Amy Pott serves as Independent Director of the Company. Ms. Pott has held leadership roles of increasing responsibility at biopharmaceutical companies primarily focused in rare disease and specialized conditions, and today serves as President, North America, for Swedish Orphan Biovitrum, also known as SOBI. She previously served as Group Vice President, US Franchise Head, Internal Medicine and Oncology at Shire Plc, and Vice President, Global Market Access and Vice President, Strategy, Planning and Analytics at Baxalta, Inc. Ms. Pott brings deep commercial expertise, having launched multiple products in rare diseases worldwide, as well as being responsible for sales, marketing, market access, analytics, strategic planning and training functions while in a variety of commercial roles. Earlier in her career, Ms. Pott focused in the payor, as well as access and reimbursement, spheres of the healthcare industry, with roles at the National Institute for Health and Care Excellence (NICE) and Baxter Healthcare Corporation.
As the Independent Director of Wave Life Sciences, the total compensation of Amy Pott at Wave Life Sciences is $258,552. There are 9 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
Amy Pott is 44, she's been the Independent Director of Wave Life Sciences since 2019. There are 14 older and 4 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
Amy's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE, MA, 02138.
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... a Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Wave Life Sciences executives and other stock owners filed with the SEC include: